Neovasc announces Neovasc Reducer included on ESC practice guidelines
Neovasc announced that its Neovasc Reducer for the treatment of patients suffering from refractory angina has been added to the European Society of Cardiology, or ESC, practice guidelines. The ESC now recommends that the Reducer might be considered for the treatment of patients with angina, refractory to medical and interventional therapies. The announcement was made at the ESC Congress. ESC Guidelines summarize and evaluate all available scientific evidence with the aim of assisting physicians in selecting the best evidence-based therapies and management strategies for an individual patient with a given condition. This set of recommendations takes into account the impact on outcomes, as well as the risk-benefit ratio of a particular diagnosis or therapy, as reflected in the available scientific data. ESC Guidelines represent the official position of the European Society of Cardiology on a given topic and are regularly updated.